



Allscripts announces first quarter 2015 results

- *Bookings total \$236 million, 6 percent year-over-year growth*
- *Recurring revenue increases to 77 from 73 percent of total revenue year-over-year*
- *Cash flow from operations totals \$59 million*

CHICAGO – May 7, 2015 – Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX) (Allscripts) announced its financial results for the three months ended March 31, 2015.

First Quarter Bookings Highlights:

Bookings⁽¹⁾ in the first quarter of 2015 were a record \$236 million compared with \$223 million in the first quarter of 2014, a 6 percent increase. First quarter 2015 bookings reflect sales growth of Sunrise™ Acute Care as well as significant contributions from population health management and Allscripts payer life sciences solutions.

Approximately 63 percent of first quarter bookings related to software delivery and recurring transactions, while the remaining 37 percent were derived from sales of client services solutions. This compares with 54 and 46 percent of bookings attributable to these revenue categories, respectively, in the first quarter of 2014.

Contract revenue backlog as of March 31, 2015, totaled \$3.5 billion, which was flat compared with the prior-year amount.

Paul M. Black, President and Chief Executive Officer of Allscripts, stated: “We are pleased with first quarter bookings growth of 6 percent year-over-year. Sunrise bookings growth reflects both net new client sales and additional sales to existing clients, as they increase investments in the platform. Enhancements in Sunrise functionality, increasing client satisfaction and recent, positive industry recognition are driving growing interest in Allscripts globally.

“While total revenue declined in the quarter, higher margin recurring revenue continues to grow year-over-year and constituted 77 percent of total revenue. We also maintained a disciplined focus on operating expenses, which helped drive a significant year-over-year increase in operating and free cash flows.” Mr. Black continued, “Looking ahead, Allscripts strategic position is solid. We are focused on continually enhancing core solutions, growing population health and international markets and offering new value-added services. Together, these opportunities provide a foundation for improving financial performance and value creation going forward.”

First Quarter 2015 Highlights

Revenue totaled \$335 million, a decline of 2 percent, compared with \$340 million in the first quarter of 2014.

Software delivery, support & maintenance revenue totaled \$228 million in the first quarter of 2015, flat compared with the first quarter of 2014. Software delivery, support & maintenance revenue consists of all software, hardware, and transaction-related revenue as well as support & maintenance.

Client services revenue totaled \$107 million in the first quarter of 2015, down 5 percent compared with the first quarter of 2014. Client services revenue consists of both managed IT services as well as other client services.

On a non-GAAP basis, recurring revenue, consisting of subscriptions, recurring transactions, support, maintenance, and recurring managed services, increased \$7 million compared with the



first quarter of 2014; representing growth of 3 percent year-over-year. Non-recurring revenue, consisting of systems sales and other client services revenue, declined \$18 million or 19 percent, compared with the first quarter of 2014.

First quarter 2015 gross margin was 42.3 percent on a non-GAAP basis and 38.8 percent on a GAAP basis, compared with 44.9 percent and 40.6 percent, respectively, in the first quarter of 2014.

Operating expenses, consisting of SG&A and R&D expense, declined 12 percent on a non-GAAP basis and 9 percent on a GAAP basis in the first quarter of 2015 compared with the first quarter of 2014. The decline in operating expenses reflects initiatives to decrease corporate SG&A expenses, streamline business functions, and leverage investments in research and development. GAAP operating expenses in the first quarter of 2015 included severance expense of approximately \$6 million.

Reflecting lower operating expenses, Adjusted EBITDA increased 4 percent to \$50 million in the first quarter of 2015, compared with \$48 million in the first quarter of 2014.

On a non-GAAP basis, Allscripts effective tax rate was 35 percent in the first quarter of both 2015 and 2014. On a GAAP basis, Allscripts recorded an income tax benefit of approximately \$1.0 million in the first quarter of 2015, compared with an income tax provision of \$1.5 million in the first quarter of 2014.

First quarter 2015 non-GAAP net income totaled \$15 million compared with \$12 million in the first quarter of 2014. First quarter 2015 GAAP net loss totaled \$10 million compared with a net loss of \$21 million in the first quarter of 2014.

First quarter 2015 non-GAAP earnings per share were \$0.08 compared with \$0.07 in the first quarter of 2014. First quarter 2015 GAAP loss per share was \$0.06 compared with a loss per share of \$0.12 in the first quarter of 2014.

Allscripts first quarter 2015 cash flow from operations totaled \$59 million compared with \$21 million in the first quarter of 2014. Free cash flow totaled \$43 million compared with \$0.2 million in the first quarter of 2014.

Allscripts is confirming its full year Adjusted EBITDA and non-GAAP earnings per diluted share that the Company introduced earlier this year. The Company is modifying its full year revenue guidance to a range between \$1.40B and \$1.43B.

For a complete reconciliation of GAAP and non-GAAP items, see the explanation of non-GAAP financial measures as well as the GAAP and non-GAAP reconciliation financial tables in this release.

Conference Call:

Allscripts will conduct a conference call today, Thursday, May 7, 2015, at 4:30 PM Eastern Time to discuss its earnings release and other information. Participants may access the conference call via webcast at <http://investor.allscripts.com>.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of two weeks, on the Allscripts investor relations website or by calling (855) 859-2056 or +1 (404) 537-3406 - Conference ID # 26615457.



Supplemental and non-GAAP financial information, including information for historical periods relating to Allscripts revised presentation of revenue and the associated cost of revenue in its consolidated statement of operations, also will be available at <http://investor.allscripts.com>.

Footnotes

- (1) Bookings reflect the value of executed contracts for software, hardware, other client services, remote hosting, outsourcing and subscription-based services.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

###

© 2015 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

For more information contact:

Investors:

Seth Frank
312-506-1213
seth.frank@allscripts.com

Media:

Concetta Di Franco
312-447-2466
Concetta.difranco@allscripts.com

Forward-Looking Statements

This earnings release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "will," "would," "could," "can," "may," and similar terms. Actual results could differ from those set forth in the forward-looking statements, and reported results should not be considered an indication of future performance. Certain factors that could cause Allscripts' actual results to differ materially from those described in the forward-looking statements include, but are not limited to: Allscripts' failure to compete successfully; consolidation in Allscripts' industry; current and future laws, regulations and industry initiatives; increased government involvement in Allscripts' industry; the failure of markets in which Allscripts operates to develop as quickly as expected; Allscripts' or its customers' failure to see the benefits of government programs; changes in interoperability or other regulatory standards; the effects of the realignment of Allscripts' sales, services, and support organizations; market acceptance of Allscripts' products and services; the unpredictability of the sales and implementation cycles for Allscripts' products and services; Allscripts' ability to manage future growth; Allscripts' ability to introduce new products and services; Allscripts' ability to establish and maintain strategic relationships; risks related to the acquisition of new companies or technologies; the performance of Allscripts' products; Allscripts' ability to protect its intellectual property rights; the outcome of legal proceedings involving Allscripts; Allscripts' ability to hire, retain and motivate key personnel; performance by Allscripts' content and service providers; liability for use of content; security breaches; price reductions;



Allscripts' ability to license and integrate third party technologies; Allscripts' ability to maintain or expand its business with existing customers; risks related to international operations; changes in tax rates or laws; business disruptions; Allscripts' ability to maintain proper and effective internal controls; and asset impairment charges. Additional information about these and other risks, uncertainties, and factors affecting Allscripts' business is contained in Allscripts' filings with the Securities and Exchange Commission. Allscripts does not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in its business, financial condition, or operating results over time.



Table 1
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)

	March 31, 2015	December 31, 2014
ASSETS		
Current assets:		
Cash and cash equivalents	\$88.5	\$53.2
Accounts receivable, net	325.2	331.6
Deferred taxes, net	35.7	35.6
Prepaid expenses and other current assets	108.0	102.4
Total current assets	<u>557.4</u>	<u>522.8</u>
Long-term marketable securities	0.0	1.3
Fixed assets, net	140.1	145.8
Software development costs, net	83.5	86.2
Intangible assets, net	387.1	403.4
Goodwill	1,200.3	1,200.7
Deferred taxes, net	0.7	0.7
Other assets	135.7	147.3
Total assets	<u><u>\$2,504.8</u></u>	<u><u>\$2,508.2</u></u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$82.7	\$70.8
Accrued expenses	63.3	79.0
Accrued compensation and benefits	39.8	51.1
Deferred revenue	322.1	293.0
Current maturities of long-term debt and capital lease obligations	30.3	27.5
Total current liabilities	<u>538.2</u>	<u>521.4</u>
Long-term debt	542.4	548.7
Deferred revenue	23.1	23.2
Deferred taxes, net	56.0	55.4
Other liabilities	67.0	75.3
Total liabilities	<u>1,226.7</u>	<u>1,224.0</u>
Total stockholders' equity	<u>1,278.1</u>	<u>1,284.2</u>
Total liabilities and stockholders' equity	<u><u>\$2,504.8</u></u>	<u><u>\$2,508.2</u></u>



Table 2
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Operations
(In millions, except per-share amounts)
(Unaudited)

	Three Months Ended March 31,	
	2015	2014
Revenue:		
Software delivery, support and maintenance	\$227.6	\$227.4
Client services	107.0	112.9
Total revenue	334.6	340.3
Cost of revenue:		
Software delivery, support and maintenance	76.7	75.2
Client services	107.2	105.9
Amortization of software development and acquisition-related assets (a)	20.9	21.0
Total cost of revenue	204.8	202.1
Gross profit	129.8	138.2
Selling, general and administrative expenses	82.1	89.9
Research and development	46.7	52.3
Asset impairment charges	0.0	0.2
Amortization of acquisition-related intangible assets	6.7	7.7
Loss from operations	(5.7)	(11.9)
Interest expense (b)	(7.3)	(7.3)
Other income, net	1.9	0.0
Loss before income taxes	(11.1)	(19.2)
Income tax benefit (provision)	1.0	(1.5)
Net loss	(\$10.1)	(\$20.7)
Loss per share - basic and diluted	(\$0.06)	(\$0.12)
Weighted average common shares outstanding:		
Basic	180.6	179.0
Diluted	180.6	179.0
(a) Amortization of software development and acquisition-related assets includes:		
Amortization of capitalized software development costs	\$11.8	\$12.2
Amortization of acquisition-related intangible assets	9.1	8.8
	\$20.9	\$21.0
(b) Interest expense includes the following non-cash expenses for the periods presented:		
	Three Months Ended March 31,	
	2015	2014
Amortization of 1.25% Cash Convertible Notes original issue discount	\$ 2.7	\$ 2.5



Table 3
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)

	Three Months Ended March 31,	
	2015	2014
Cash flows from operating activities:		
Net loss	(\$10.1)	(\$20.7)
Non-cash adjustments to net loss:		
Depreciation and amortization	41.7	45.1
Stock-based compensation expense	9.1	10.1
Other non-cash charges, net	0.0	4.9
Total non-cash adjustments to income	50.8	60.1
Cash impact of changes in operating assets and liabilities	17.8	(18.1)
Net cash provided by operating activities	58.5	21.3
Cash flows from investing activities:		
Capital expenditures	(6.1)	(11.9)
Capitalized software	(9.3)	(9.2)
Purchases of non-marketable securities and other investments	(0.7)	(6.0)
Sales and maturities of marketable securities and other investments	1.3	0.0
Proceeds from sale of fixed assets	0.0	0.1
Net cash used in investing activities	(14.8)	(27.0)
Cash flows from financing activities:		
Stock-based compensation-related payments, net	(2.2)	(0.4)
Senior secured debt borrowings payments, net	(5.7)	(15.4)
Net cash (used in) provided by financing activities	(7.9)	(15.8)
Effect of exchange rate changes on cash and cash equivalents	(0.5)	0.1
Net increase (decrease) in cash and cash equivalents	35.3	(21.4)
Cash and cash equivalents, beginning of period	53.2	63.0
Cash and cash equivalents, end of period	\$88.5	\$41.6



Table 4
Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per share amounts)
(Unaudited)

	Three Months Ended March 31,	
	2015	2014
Total revenue, as reported	\$334.6	\$340.3
Deferred revenue and other adjustments	0.0	4.5
Total non-GAAP revenue	\$334.6	\$344.8
Gross profit, as reported	\$129.8	\$138.2
Deferred revenue and other adjustments	0.0	4.5
Acquisition-related amortization	9.1	8.8
Stock-based compensation expense	2.5	1.3
Non-recurring expenses and transaction-related costs (a)	0.0	1.9
Total non-GAAP gross profit	\$141.4	\$154.7
Operating income (loss), as reported	(\$5.7)	(\$11.9)
Deferred revenue and other adjustments	0.0	4.5
Acquisition-related amortization	15.8	16.5
Stock-based compensation expense	9.5	10.1
Non-recurring expenses and transaction-related costs (a)	6.1	3.7
Non-cash asset impairment charges	0.0	0.2
Total non-GAAP operating income	\$25.7	\$23.1
Net loss, as reported	(\$10.1)	(\$20.7)
Deferred revenue and other adjustments	0.0	2.9
Acquisition-related amortization	10.3	10.7
Stock-based compensation expense	6.2	6.5
Non-recurring expenses and transaction-related costs	3.9	2.4
Non-cash asset impairment charges	0.0	0.1
Non-cash charges to interest expense and other	1.7	1.8
Tax rate alignment	2.9	8.3
Non-GAAP net income	\$14.9	\$12.0
Non-GAAP effective tax rate	35%	35%
Weighted shares outstanding - diluted	180.6	179.0
Loss per share - diluted, as reported	(\$0.06)	(\$0.12)
Non-GAAP earnings per share - diluted	\$0.08	\$0.07

Note: all adjustments to reconcile GAAP to non-GAAP net income are net of tax.

(a) Non-recurring expenses and transaction-related costs included in cost of revenue and operating expenses are comprised of the following for the periods presented:

	Three Months Ended March 31,	
	2015	2014
Cost of revenue:		
MyWay and other product consolidation costs included in cost of revenue	\$0.0	\$1.9
Operating expenses:		
Severance and other costs	\$6.0	\$0.1
MyWay product consolidation	0.0	0.0
Transaction-related costs	0.1	1.7
Total non-recurring expenses and transaction-related costs included in operating expenses	\$6.1	\$1.8
Total non-recurring expenses and transaction related costs	\$6.1	\$3.7



Table 5
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - Adjusted EBITDA
(In millions)
(Unaudited)

	Three Months Ended March 31,	
	2015	2014
Total revenue, as reported	\$334.6	\$340.3
Deferred revenue and other adjustments	0.0	4.5
Total non-GAAP revenue	\$334.6	\$344.8
Net loss, as reported	(\$10.1)	(\$20.7)
Deferred revenue and other adjustments	0.0	4.5
Depreciation and amortization	41.7	45.1
Stock-based compensation expense	9.5	10.1
Non-recurring expenses and transaction-related costs (a)	6.1	3.2
Non-cash asset impairment charges	0.0	0.2
Interest expense and other income net (b)	3.7	4.0
Tax provision/(benefit)	(1.0)	1.5
Adjusted EBITDA	\$49.9	\$47.9
<i>Adjusted EBITDA margin (c)</i>	<i>15%</i>	<i>14%</i>

(a) Depreciation expense totaling \$0.0 million and \$0.5 million has been excluded from non-recurring expenses for the three months ended March 31, 2015 and 2014 respectively, since these amounts are also included in depreciation and amortization.

(b) Interest expense (income) and other (income) expense has been adjusted from the amounts presented in the statements of operations in order to remove the amortization of the fair value of the cash conversion option embedded in the 1.25% Cash Convertible Notes and deferred debt issuance costs from interest expense since such amortization is also included in depreciation and amortization.

(c) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by total non-GAAP revenue.



Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this release non-GAAP revenue, gross profit, SG&A, operating expense, operating income and net income, including non-GAAP net income on a per share basis, non-GAAP effective income tax rate, and Adjusted EBITDA and free cash flow, which are also considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended.

- Non-GAAP revenue consists of GAAP revenue as reported and adds back deferred revenue and other adjustments recorded for GAAP purposes.
- Non-GAAP gross profit consists of GAAP gross profit as reported and adds back deferred revenue and other adjustments booked for GAAP purposes and excludes acquisition-related amortization, stock-based compensation expense, and non-recurring expenses and transaction-related costs. Non-GAAP gross margin consists of non-GAAP gross profit as a percentage of non-GAAP revenue, as defined above. For the first quarter of 2015, non-GAAP gross margin totaled 42.3 percent, consisting of non-GAAP gross profit of \$141.4 million divided by total non-GAAP revenue of \$334.6 million. For the first quarter of 2014, non-GAAP gross margin totaled 44.9 percent consisting of non-GAAP gross profit of \$154.7 million divided by total non-GAAP revenue of \$344.8 million. Reconciliations to total non-GAAP revenue and total non-GAAP gross profit are found in Table 4 within this press release.
- Non-GAAP operating expense consists of GAAP selling, general and administrative expenses (SG&A) and research and development expense (R&D), as reported, and excludes non-recurring expenses and transaction-related costs and stock-based compensation expense recorded to SG&A and R&D. For the first quarter of 2015, non-GAAP operating expense totaled \$115.7 million consisting of \$82.1 million of GAAP SG&A and \$46.7 million of GAAP R&D expense and excludes \$6.1 million of total non-recurring expense and transaction-related costs and \$7.0 million of stock-based compensation expense recorded to SG&A and R&D. For the first quarter of 2014, non-GAAP operating expense totaled \$131.6 million consisting of \$89.9 million of GAAP SG&A and \$52.3 million of GAAP R&D expense and excludes \$1.8 million of total non-recurring expense and transaction-related costs and \$8.8 million of stock-based compensation expense recorded to SG&A and R&D.
- Adjusted EBITDA is a non-GAAP measure and consists of GAAP net income (loss) as reported and adjusts for: tax provision (benefit); interest expense and other income, net; stock-based compensation expense; depreciation and amortization; deferred revenue and other adjustments; non-recurring and transaction-related costs; and non-cash asset impairment charges.
- Non-GAAP effective income tax rate is based on non-GAAP pre-tax earnings and consists of the statutory federal income rate, Allscripts effective state income tax rate, and adjustments for permanent differences.
- Non-GAAP net income consists of GAAP net income/(loss) as reported, and adds back deferred revenue and other adjustments, acquisition-related amortization, stock-based compensation expense, non-recurring expenses and transaction-related costs, non-cash charges to interest expense and other, and non-cash asset impairment charges, in each case net of any related tax effects. Non-GAAP net income also includes a tax rate alignment adjustment.



Deferred Revenue and Other Adjustments. Deferred revenue and other adjustments includes acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in business acquisitions. The fair value of deferred revenue represents an amount equivalent to the estimated cost plus an appropriate profit margin, to perform services related to the acquiree's software and product support, which assumes a legal obligation to do so, based on the deferred revenue balances as of the acquisition date. Also included are adjustments for the vesting of a warrant issued to a commercial partner and the effects of straight-lining contractual pricing adjustments over the performance period. Allscripts adds back deferred revenue and other adjustments for its non-GAAP financial measures because it believes the inclusion of this amount directly correlates to the underlying performance of Allscripts operations.

Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP operating income and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.

Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards to employees. Allscripts excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP operating income, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods and such expense will recur in future periods.

Non-Recurring Expenses and Transaction-Related Costs. Non-recurring expenses relate to certain severance, product consolidation, legal proceedings, consulting, and other charges incurred in connection with activities that are considered one-time. Transaction-related costs include deferred compensation expenses incurred in connection with the acquisition of dbMotion, Ltd.

Allscripts excludes non-recurring expenses and transaction-related costs from non-GAAP gross profit, non-GAAP operating income, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods.

Non-Cash Charges to Interest Expense and Other. Non-cash charges to interest expense and other includes non-cash amortization of the fair value of the cash conversion option embedded in the 1.25 percent Cash Convertible Notes issued by Allscripts during the second quarter of 2013. Also included in this amount are non-cash adjustments to reflect changes in the fair value of derivative financial instruments related to the 1.25 percent Cash Convertible Notes that do not qualify for hedge accounting treatment.



Non-Cash Asset Impairment Charges. Asset impairment charges relate primarily to product consolidation activities.

Tax Rate Alignment. Tax adjustment aligns the applicable period's effective tax rate to the expected annual non-GAAP effective tax rate.

Management also believes that non-GAAP revenue, gross profit, SG&A, operating expense, operating income, net income and non-GAAP net income on a per share basis, and Adjusted EBITDA, provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein. Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP revenue, SG&A, operating expense, operating income, net income and/or Adjusted EBITDA to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis and Adjusted EBITDA are performance measures only, and they do not provide any measure of cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

Free Cash Flow. Free cash flow is calculated based on GAAP cash flows provided by operating activities in the applicable period, net of capital expenditures and capitalized software costs. For the first quarter of 2015, cash flow from operations totaled \$58.5 million, capital expenditures totaled \$6.1 million and capitalized software totaled \$9.3 million. For the first quarter of 2014, cash flow from operations totaled \$21.3 million, capital expenditures totaled \$11.9 million and capitalized software totaled \$9.2 million.